Femasys, Inc. FEMY
NASDAQ · United States · Electronic Technology
$2.10-0.06 (-2.78%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
-- Leading multi-site OB/GYN health practice to implement FemVue® for fertility diagnostic evaluation and FemaSeed for first-line treatment across all four locations -- ATLANTA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that Minnesota Women’s Care w
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Collaboration provides dedicated patient financing for Femasys fertility solutions, helping reduce financial barriers to care across OB/GYN practices and fertility centersATLANTA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today a partnership with CapexMD
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.